Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma - Takeaways - MDSpire

Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma

  • By

  • Kevin Charles Miller

  • Patrick Connor Johnson

  • Jeremy S. Abramson

  • Jacob D. Soumerai

  • Andrew J. Yee

  • Andrew R. Branagan

  • Elizabeth K. O’Donnell

  • Anna Saucier

  • Caron A. Jacobson

  • Matthew J. Frigault

  • Noopur S. Raje

  • November 1, 2022

  • 0 min

Share

  • 1

    CAR T therapy significantly improves outcomes for lymphoma and multiple myeloma but is associated with severe immune toxicities.

  • 2

    Granulocyte colony-stimulating factor (G-CSF) is used to manage neutropenia post-CAR T, but its optimal use remains unclear due to potential exacerbation of toxicities.

  • 3

    High levels of serum G-CSF and GM-CSF correlate with severe neurotoxicity, raising concerns about the safety of G-CSF administration in CAR T patients.

  • 4

    The study retrospectively analyzed CAR T patients to evaluate the impact of G-CSF on CRS, ICANS, and neutropenia, aiming to inform future clinical guidelines.

  • 5

    Current guidelines vary, with some recommending avoidance of G-CSF until three weeks post-CAR T, highlighting the need for standardized protocols.

Original Source(s)

Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma

  • by Kevin Charles Miller, Patrick Connor Johnson, Jeremy S. Abramson, Jacob D. Soumerai, Andrew J. Yee, Andrew R. Branagan, Elizabeth K. O’Donnell, Anna Saucier, Caron A. Jacobson, Matthew J. Frigault, Noopur S. Raje

  • November 1, 2022

Related Content

Using period analysis to timely provide serial data on long-term survival for patients with hematological malignancies from Taizhou, Eastern China

An ASCO preview: What to watch for at cancer research’s big meeting

Prognostic nutritional index, but not NLR or PLR, is linked to survival in multiple myeloma